Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome

Widera, Christian; Gupta, Shashi; Lorenzen, Johan M.; Bang, Claudia; Bauersachs, Johann; Bethmann, Kerstin; Kempf, Tibor; Wollert, Kai C.; Thum, Thomas

doi:10.1016/j.yjmcc.2011.07.011

Cited by 349 publications

(323 citation statements)

References 18 publications

Supporting

Mentioning

296

Contrasting

Unclassified

Order By: Relevance

“…miRNAs are generally believed to act as endogenous intracellular modulators of genetic information. However, recent studies have shown that miRNAs are remarkably stable in blood and other body fluids and thus, may be useful as biomarkers of disease activity (11)(12)(13)(14). Interestingly, circulating miRNAs may transfer genetic information from a donor to a recipient cell, thereby altering cellular biologic processes by influencing the transcriptional program (15).…”

Section: Introductionmentioning

confidence: 99%

Circulating and Urinary microRNAs in Kidney Disease

Lorenzen

Thum

2012

Clinical Journal of the American Society of Nephrology

Self Cite

View full text Add to dashboard Cite

Summary microRNAs are small, noncoding RNAs that control gene/protein expression through target messengerRNA degradation and/or inhibition of protein synthesis. An array of experimental studies has shown the importance of microRNAs for disease initiation/progression. microRNAs are generally considered to act as intracellular modulators of gene expression. However, first studies in the cancer and cardiovascular field have elucidated that microRNAs are remarkably stable in the extracellular compartment (e.g., in blood or urine). The detection and quantification of circulating microRNAs may, thus, represent a novel noninvasive tool to detect and monitor disease activity. In addition, there might be a potential biologic relevance of circulating microRNAs for cell/cell communication. The aim of the present article is to give an outline of recent work on circulating and urinary microRNAs as well as their potential paracrine activity in kidney disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Circulating and Urinary microRNAs in Kidney Disease

Lorenzen

Thum

2012

Clinical Journal of the American Society of Nephrology

Self Cite

View full text Add to dashboard Cite

show abstract

“…The plasma levels of miRNA-1, -133a, -133b, and -499-5p are upregulated in AMI patient, and represent novel biomarkers of cardiac damage. Several reviews have provided an over-view of biology of miRNA-1, miRNA-133b, -499-5p and their involvement in cardiovascular physiology and pathology, and discussed the potential of these miRNAs to become a novel biomarker of AMI and even an effective therapeutics agent (4)(5)(6)(7)(8). miRNA-499 is a newly discovered member of miRNAs encoded by myosin gene family, and its expression level in plasma was elevated in the patients with AMI, a common heart disease that is the leading cause of morbidity and mortality worldwide (9).…”

mentioning

confidence: 99%

Circulating miR-499 as a potential biomarker for acute myocardial infarction

Xin¹,

Yang²,

Han³

2016

Ann. Transl. Med.

View full text Add to dashboard Cite

Acute myocardial infarction (AMI), a common heart disease that may lead to chronic heart failure, is the leading cause of morbidity and mortality worldwide. MicroRNAs (miRNAs) are small non-coding RNAs that mediate the expression of target genes. Recently, a number of miRNAs are emerging as potential biomarkers of AMI. MiRNA-499 is a newly discovered member of miRNAs, and is mainly expressed in myocardium, the circulating levels of miRNA-499 was increased in AMI patients. This review summarizes the latest advances in the miRNA-499 study and discusses the potential of miRNA-499 to be a biomarker of AMI. Acute myocardial infarction (AMI) is one of the leading causes of morbidity and mortality worldwide, thus an effective and accurate diagnostic biomarker would be needed to help decrease the mortality of AMI patients. One of the traditional biomarkers for AMI is troponin. Circulating troponin levels rise around 3 hours after the onset of chest pain, due to the relative delayed release time of troponin. It is widely believed that a rapid and correct diagnosis of AMI has an important impact on patients' treatment and prognosis. Therefore, earlier biomarkers than troponin with both high sensitivity and specificity remain to be needed. MicroRNAs (miRNAs) are endogenous small non-coding RNAs of less than 22 nucleotides that are implicated in nearly all cellular events including cell differentiation and proliferation as well as the pathogenesis of certain human diseases (1,2). Recently, a number of findings support the notion of the implication of miRNAs in the development and progression of cardiovascular diseases (3). The plasma levels of miRNA-1, -133a, -133b, and -499-5p are upregulated in AMI patient, and represent novel biomarkers of cardiac damage. Several reviews have provided an over-view of biology of miRNA-1, miRNA-133b, -499-5p and their involvement in cardiovascular physiology and pathology, and discussed the potential of these miRNAs to become a novel biomarker of AMI and even an effective therapeutics agent (4-8). miRNA-499 is a newly discovered member of miRNAs encoded by myosin gene family, and its expression level in plasma was elevated in the patients with AMI, a common heart disease that is the leading cause of morbidity and mortality worldwide (9). A previous study compared the diagnostic performance of miRNA-499 and some traditional biomarkers like SMB, cTnI, cTnT, CK-MB, CK, LDH, and concluded that miRNA-499 was present in plasma earlier than other conventional biomarkers of AMI, pointing to the likelihood that miR-499 can be a vital molecule in the early diagnosis of AMI. This study also found that the circulating level of miR-499 correlated well with circulating troponin I

show abstract

“…Particularly interesting from the clinical point of view are results from a study by Widera et al, who assessed diagnostic value of six circulating miRNAs in 444 subjects with acute coronary syndrome (miRNA-1, miR-NA-133a, miRNA-208a/b and miRNA-499). In this study, subjects with myocardial infarction presented with significantly higher levels of miRNA-208b, miR-NA-133a and miRNA-1 (39). Recently, in meta-analysis Cheng et al summarized and analyzed the role of circulating miRNAs (miRNA-1, miRNA-133a, miR-NA-208a, miRNA-499) in the diagnosis of AMI.…”

Section: Mirna-208mentioning

confidence: 61%

MicroRNAs as biomarkers for acute myocardial infarction: Small molecules with a huge potential

Miśkowiec¹,

Kasprzak²

2015

SANAMED

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are a conserved class of small, 17-25 nucleotides long, noncoding RNAs. They act as controllers of gene expression patterns, either by blocking translation or inducing miR-NA degradation by sequence-specific hybridization. Several miRNAs have been proposed as potential disease-specific biomarker in cardiovascular diseases. The diagnostic value of assessing circulating miRNAs levels has been evaluated in numerous studies, mainly regarding acute myocardial infarction. Initial promising results from preclinical studies suggest the potential for future miRNA-based therapies. In our review, we focus on the current developments showing the role of miRNAs in the acute myocardial infarction, emphasizing diagnostic utility of miRNAs as promising new biomarkers of AMI and their therapeutic potential.

show abstract

Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome

Cited by 349 publications

References 18 publications

Circulating and Urinary microRNAs in Kidney Disease

Circulating and Urinary microRNAs in Kidney Disease

Circulating miR-499 as a potential biomarker for acute myocardial infarction

MicroRNAs as biomarkers for acute myocardial infarction: Small molecules with a huge potential

Contact Info

Product

Resources

About